Vincenzo Nicola Talesa

Vincenzo Nicola Talesa

Auto-generated profile, based on publicly available information

Vincenzo Nicola Talesa

Department of Experimental Medicine and Biochemical Sciences, University of Perugia, Perugia, Italy

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2001 in Mechanisms of Ageing and Development
Verified
Journal Article
Closed access
VTVincenzo Nicola Talesa
Vincenzo Nicola Talesa

20 April 2009 in BMC Cancer
Verified
Journal Article
Open access
PDF file
Cinzia AntognelliCinzia Antognelli
Cinzia Antognelli
CBChiara Del Buono
Chiara Del Buono
VLVienna Ludovini
Vienna Ludovini
SGStefania Gori
Stefania Gori
VTVincenzo N Talesa
Vincenzo N Talesa
ARAntonio Rulli
Antonio Rulli
Estrogens, environmental chemicals with carcinogenic potential, as well as oxidative and carbonyl stresses play a very important role in breast cancer (BC) genesis and progression. Therefore, polymorphisms of genes encoding enzymes involved in estrogen biosynthesis pathway and in the metabolic activation of pro-carcinogens to genotoxic intermediates, such as cytochrome P450C17α (CYP17), endogenous free-radical scavenging systems, such as glutathione S-transferase (GSTP1) and paraoxonase 1 (PON1), and anti-glycation defenses, such as glyoxalase I (GLO1), could influence individual susceptibility to BC. In the present case-control study, we investigated the possible association of CYP17 A1A2, GSTP1 ILE105VAL, PON1 Q192R or L55M, and GLO1 A111E polymorphisms with the risk of BC.

1 June 2012 in The Prostate
Verified
Journal Article
Closed access
PDF file
Cinzia AntognelliCinzia Antognelli
Cinzia Antognelli
LMLetizia Mezzasoma
Letizia Mezzasoma
KFKatia Fettucciari
Katia Fettucciari
EMEttore Mearini
Ettore Mearini
VTVincenzo N. Talesa
Vincenzo N. Talesa

10 September 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Cinzia AntognelliCinzia Antognelli
Cinzia Antognelli
LMLetizia Mezzasoma
Letizia Mezzasoma
EMEttore Mearini
Ettore Mearini
VTVincenzo Nicola Talesa
Vincenzo Nicola Talesa
Glyoxalase 1 is a scavenging enzyme of potent precursors in reactive oxygen species formation and is involved in the occurrence and progression of human malignancies. Glyoxalase I A111E polymorphism has been suggested to influence its enzymatic activity. The present study was aimed at investigating the association of this polymorphism with oxidative stress and its implications in prostate cancer progression or survival. The polymorphism was genotyped in human differently aggressive and invasive prostate cancer cell lines, in 571 prostate cancer or 588 benign prostatic hyperplasia patients, and 580 healthy subjects by Polymerase Chain Reaction/Restriction Fragment Length Polymorphism. Glyoxalase 1 activity, the pro-oxidant Glyoxalase 1-related Argpyrimidine and oxidative stress biomarkers were evaluated by biochemical analyses. Glyoxalase 1 polymorphism was associated with an increase in Glyoxalase 1-related pro-oxidant Argpyrimidine and oxidative stress levels and cancer progression. The mutant A allele conferred a modest risk of prostate cancer, a marked risk of prostate cancer progression and a lower survival time, compared to the wild C allele. The results of our exploratory study point out a significant role for Glyoxalase 1 in prostate cancer progression, providing an additional candidate for risk assessment in prostate cancer patients and an independent prognostic factor for survival. Finally, we provided evidence of the biological plausibility of Glyoxalase 1 polymorphism, either alone or in combination with other ones, all related to oxidative stress control that represents a key event in PCa development and progression.

13 March 2009 in Biomarkers
Verified
Journal Article
Closed access
EMEttore Mearini
Ettore Mearini
Cinzia AntognelliCinzia Antognelli
Cinzia Antognelli
CBChiara Del Buono
Chiara Del Buono
Giovanni CochettiGiovanni Cochetti
Giovanni Cochetti
AGAntonella Giannantoni
Antonella Giannantoni
VTVincenzo N. Talesa
Vincenzo N. Talesa
The identification of reliable molecular biomarkers in prostate cancer early diagnosis is clinically desirable. We quantitatively detected prostate cancer specifically overexpressed genes, DD3 and PSA, in urine sediments of men suffering from prostate cancer or benign prostate hyperplasia, after prostatic massage. As both genes are exclusively expressed in androgen receptor expressing human prostate carcinoma cell lines, we further investigated the possible effect of androgens on PSA and DD3 gene expression. DD3 and PSA mRNA levels were measured by real-time polymerase chain reaction. The combined markers test had a sensitivity of 80.2% and a specificity of 100%. Both gene transcripts were significantly upregulated by androgens. Results indicated the clinical usefulness of the combination of DD3 and PSA as molecular markers in the early diagnosis of prostate cancer and the need of combining as many as possible analytical data with the clinical and demographic ones to achieve the maximum level of diagnostic accuracy.

22 December 2009 in Cancer Biomarkers
Verified
Journal Article
Closed access
PDF file
VTVincenzo N. Talesa
Vincenzo N. Talesa
Cinzia AntognelliCinzia Antognelli
Cinzia Antognelli
CBChiara Del Buono
Chiara Del Buono
FSFabrizio Stracci
Fabrizio Stracci
MSMaria R. Serva
Maria R. Serva
EMEttore Mearini
Ettore Mearini
Prostate cancer (PCa) is a heterogeneous, multifactorial and multifocal disease. Therefore, the search for a combination of assays using a panel of tumor markers is fundamental for a more precise and reliable diagnosis. In the present study we invest